Curigliano G, Dunton K, Rosenlund M, Janek M, et al. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 study. Ann Oncol 2023 May 11:S0923-7534(23)00677-4. doi: 10.1016/j.annonc.2023.
PMID: 37179020